Dermal Regeneration Market Size is expected to gain commendable traction from 2022 to 2028, due to the increasing availability of dermal regeneration templates designed to help protect wound infection, thus enabling regrowth of functional dermal skin layers. Their rising usage as scaffolds for neodermis formation to provide a viable skin graft recipient site in areas where primary skin grafting technique is not indicated will also contribute to industry growth over the years ahead. Skin regeneration of the dermis and epidermis refers to a technique used to lower the risk of infections and mortality, as they provide permanent or temporary wound coverage. The dermis is the skin’s mesenchymal component and comprises two structurally different layers namely the reticular and papillary layers. Dermal template and staged skin grafting have significantly emerged as a reliable option for the reconstruction of the post-cancer scalp in poor flap candidates.
Mounting prevalence of chronic diseases including diabetes is one of the key factors fostering the dermal regeneration market trends over 2022-2028. According to the National Diabetes Statistics Report, 2020 released by the CDC, nearly 34.2 million Americans have diabetes. This factor could augment industry demand, given the use of dermal regeneration matrix in the treatment of diabetic foot ulcers. Likewise, the global burden of traumatic injuries, coupled with the surging incidence of burns, especially among adults in the U.S., will further generate opportunities for industry expansion over the estimated timeline.
Considering source, the silicone segment will account for a major share in the dermal regeneration market by 2028. This can be credited to the significant usage of pressure therapy, silicone and lasers as an effective intervention window for scar prevention after wound healing. Based on end-use, the hospitals segment will amass considerable gains over the coming years, owing to the increased hospital admissions due to road accidents globally.
From a regional perspective, the North America the dermal regeneration market is poised to exhibit a high growth rate through 2028, driven by the high emphasis on boosting government funding on stem cell research. As stem cells are gaining interest due to their highly regenerative potential as well as participation in wound healing, this potential rise in spending could contribute to the development of dermal stem cell regeneration techniques. Furthermore, the robust presence of hospitals with dedicated pediatric burn scar reconstruction programs will also contribute to the regional market dynamics in the upcoming years.
Some of the key players in the dermal regeneration industry include Symatese, Stratatech Corporation (Mallinckrodt), Platelet BioGenesis, Smith & Nephew, Canton, Organogenesis Holdings, Integra LifeSciences, Advanced BioHealing, and Acell, among others. These companies are focusing on new product launches, collaborations, and acquisitions to expand their businesses in the competitive market. For instance, in June 2021, Mallinckrodt Plc gained approval from the U.S. FDA for StrataGraft, their allogeneic cultured keratinocytes as well as dermal fibroblasts in murine collagen-dsat, designed to treat adults with thermal burns.
The unprecedented impacts of the novel coronavirus outbreak and its resultant lockdowns have led to temporary suspensions of outpatient wound care clinics worldwide. Due to the fear of contracting the virus, several patients chose to avoid appointments even after the ease of movement restrictions. These disruptions in normal wound care practices during the crises may have created a hindrance to the steady growth of the dermal regeneration industry over the past months. However, the rising awareness about the risks and complications among COVID-19 patients with traumatic injuries may aid industry recovery over the foreseeable future.
Market, by Source
Market, by Application
Market, by End-use
The above information is provided for the following regions and countries: